620 related articles for article (PubMed ID: 30354558)
1. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
Van Tassell BW; Canada J; Carbone S; Trankle C; Buckley L; Oddi Erdle C; Abouzaki NA; Dixon D; Kadariya D; Christopher S; Schatz A; Regan J; Viscusi M; Del Buono M; Melchior R; Mankad P; Lu J; Sculthorpe R; Biondi-Zoccai G; Lesnefsky E; Arena R; Abbate A
Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141858
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).
Van Tassell BW; Buckley LF; Carbone S; Trankle CR; Canada JM; Dixon DL; Abouzaki N; Oddi-Erdle C; Biondi-Zoccai G; Arena R; Abbate A
Clin Cardiol; 2017 Sep; 40(9):626-632. PubMed ID: 28475816
[TBL] [Abstract][Full Text] [Related]
4. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
[TBL] [Abstract][Full Text] [Related]
5. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).
Van Tassell BW; Arena R; Biondi-Zoccai G; Canada JM; Oddi C; Abouzaki NA; Jahangiri A; Falcao RA; Kontos MC; Shah KB; Voelkel NF; Dinarello CA; Abbate A
Am J Cardiol; 2014 Jan; 113(2):321-327. PubMed ID: 24262762
[TBL] [Abstract][Full Text] [Related]
6. Cardiopulmonary exercise testing reflects similar pathophysiology and disease severity in heart failure patients with reduced and preserved ejection fraction.
Guazzi M; Labate V; Cahalin LP; Arena R
Eur J Prev Cardiol; 2014 Jul; 21(7):847-54. PubMed ID: 23382540
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction.
Nadruz W; West E; Sengeløv M; Santos M; Groarke JD; Forman DE; Claggett B; Skali H; Shah AM
J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29089342
[TBL] [Abstract][Full Text] [Related]
8. Explanation of the variance in quality of life and activity capacity of patients with heart failure by laboratory data.
Athanasopoulos LV; Dritsas A; Doll HA; Cokkinos DV
Eur J Cardiovasc Prev Rehabil; 2010 Aug; 17(4):375-9. PubMed ID: 19940776
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO
Klaassen SHC; Liu LCY; Hummel YM; Damman K; van der Meer P; Voors AA; Hoendermis ES; van Veldhuisen DJ
J Card Fail; 2017 Nov; 23(11):777-782. PubMed ID: 28736291
[TBL] [Abstract][Full Text] [Related]
10. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction.
Buckley LF; Canada JM; Del Buono MG; Carbone S; Trankle CR; Billingsley H; Kadariya D; Arena R; Van Tassell BW; Abbate A
ESC Heart Fail; 2018 Apr; 5(2):372-378. PubMed ID: 29345112
[TBL] [Abstract][Full Text] [Related]
11. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
Lewis GD; Malhotra R; Hernandez AF; McNulty SE; Smith A; Felker GM; Tang WHW; LaRue SJ; Redfield MM; Semigran MJ; Givertz MM; Van Buren P; Whellan D; Anstrom KJ; Shah MR; Desvigne-Nickens P; Butler J; Braunwald E;
JAMA; 2017 May; 317(19):1958-1966. PubMed ID: 28510680
[TBL] [Abstract][Full Text] [Related]
12. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
[TBL] [Abstract][Full Text] [Related]
13. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
Fudim M; Kelly JP; Jones AD; AbouEzzeddine OF; Ambrosy AP; Greene SJ; Reddy YNV; Anstrom KJ; Alhanti B; Lewis GD; Hernandez AF; Felker GM
Am Heart J; 2020 Feb; 220():97-107. PubMed ID: 31805424
[TBL] [Abstract][Full Text] [Related]
14. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
15. Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection Fraction: The RAPID-HF Randomized Clinical Trial.
Reddy YNV; Koepp KE; Carter R; Win S; Jain CC; Olson TP; Johnson BD; Rea R; Redfield MM; Borlaug BA
JAMA; 2023 Mar; 329(10):801-809. PubMed ID: 36871285
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
17. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA
JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154
[TBL] [Abstract][Full Text] [Related]
18. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study.
Van Tassell B; Mihalick V; Thomas G; Marawan A; Talasaz AH; Lu J; Kang L; Ladd A; Damonte JI; Dixon DL; Markley R; Turlington J; Federmann E; Del Buono MG; Biondi-Zoccai G; Canada JM; Arena R; Abbate A
J Transl Med; 2022 Jun; 20(1):270. PubMed ID: 35706006
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
